Research analysts have, from time to time, published material commenting on BTG. Any opinions, estimates or forecasts regarding the Company's performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. You should, therefore, not place undue reliance on the content of any such analyst report or statement. The following analysts currently issue reports on us:
|Daniel Stewart||Vadim Alexandre|
|Deutsche Bank||Richard Parkes|
|Edison Investment Research||Robin Davison|
|J.P. Morgan Cazenove||James Gordon|
|New Street Research||Chris Donnellan|
|Nomura Code||Gary Waanders|
|Panmure Gordon||Savvas Neophytou|
|Peel Hunt||Paul Cuddon|
|Shore Capital||Brian White|
These reports cannot be obtained directly from us. Any reports issued may have become out of date following publication and should be read accordingly.
We regained US sales and marketing rights for two of our specialty pharmaceutical products in October 2010. In January 2012 we also regained US sales and marketing rights for our bead products. We now sell these products direct through our specialist sales teams, enabling us benefit from 100% of the sales revenues.
We have a variety of different investor and shareholder contacts depending on the nature of your enquiry.